[go: up one dir, main page]

DK3774789T3 - BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse - Google Patents

BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3774789T3
DK3774789T3 DK19717685.2T DK19717685T DK3774789T3 DK 3774789 T3 DK3774789 T3 DK 3774789T3 DK 19717685 T DK19717685 T DK 19717685T DK 3774789 T3 DK3774789 T3 DK 3774789T3
Authority
DK
Denmark
Prior art keywords
brm
associated methods
targeted compounds
targeted
compounds
Prior art date
Application number
DK19717685.2T
Other languages
English (en)
Inventor
Andrew P Crew
Jing Wang
Michael Berlin
Peter DRAGOVICH
Huifen Chen
Leanna Staben
Original Assignee
Arvinas Operations Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Genentech Inc filed Critical Arvinas Operations Inc
Application granted granted Critical
Publication of DK3774789T3 publication Critical patent/DK3774789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK19717685.2T 2018-04-01 2019-04-01 BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse DK3774789T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651186P 2018-04-01 2018-04-01
US201962797754P 2019-01-28 2019-01-28
PCT/US2019/025254 WO2019195201A1 (en) 2018-04-01 2019-04-01 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
DK3774789T3 true DK3774789T3 (da) 2025-06-10

Family

ID=66175525

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19717685.2T DK3774789T3 (da) 2018-04-01 2019-04-01 BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse

Country Status (28)

Country Link
US (2) US20190300521A1 (da)
EP (2) EP3774789B1 (da)
JP (3) JP7721270B2 (da)
KR (2) KR20240130153A (da)
CN (2) CN120504668A (da)
AU (3) AU2019249849C1 (da)
BR (1) BR112020020196A2 (da)
CA (1) CA3094305A1 (da)
CL (1) CL2020002546A1 (da)
CO (1) CO2020013762A2 (da)
CR (1) CR20200527A (da)
DK (1) DK3774789T3 (da)
ES (1) ES3027032T3 (da)
FI (1) FI3774789T3 (da)
HR (1) HRP20250617T1 (da)
HU (1) HUE071391T2 (da)
IL (1) IL277677A (da)
LT (1) LT3774789T (da)
MX (2) MX2020010368A (da)
MY (1) MY198308A (da)
PE (1) PE20212108A1 (da)
PH (1) PH12020500663A1 (da)
PL (1) PL3774789T3 (da)
PT (1) PT3774789T (da)
RS (1) RS66841B1 (da)
SG (1) SG11202008898UA (da)
SI (1) SI3774789T1 (da)
WO (1) WO2019195201A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010368A (es) * 2018-04-01 2021-01-08 Arvinas Operations Inc Compuestos dirigidos a brm y métodos de uso asociados.
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
EP3784665A4 (en) * 2018-04-26 2022-01-26 Aurigene Discovery Technologies Limited PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
WO2019213005A1 (en) 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP3917526A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
WO2021067606A1 (en) * 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12410152B2 (en) 2019-10-16 2025-09-09 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
AU2020368542B2 (en) 2019-10-17 2024-02-29 Arvinas Operations, Inc. Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety
CN114599428A (zh) * 2019-10-28 2022-06-07 豪夫迈·罗氏有限公司 双功能化合物
JP2023511472A (ja) * 2019-10-29 2023-03-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二官能性化合物
BR112022012410A2 (pt) * 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
AU2021205326A1 (en) * 2020-01-10 2022-07-21 Amgen Inc. SMARCA2-VHL degraders
EP4097096A4 (en) * 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2021155225A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230096160A1 (en) * 2020-02-12 2023-03-30 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
BR112022025061A2 (pt) * 2020-06-09 2023-01-31 Prelude Therapeutics Inc Compostos que estabelecem como alvo brm e métodos de uso associados
KR20230042032A (ko) * 2020-07-21 2023-03-27 제넨테크, 인크. Brm 분해의 항체 접합 화학 유도제 및 이의 방법
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
IL300387A (en) * 2020-08-04 2023-04-01 Aurigene Oncology Ltd 6-mutated pyridazine compounds as SMARCA2 and/or SMARCA4 derivatives
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
WO2022099117A1 (en) 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
EP4259612A4 (en) * 2020-12-09 2025-06-25 Kymera Therapeutics, Inc. SMARCA DEGRADERS AND USES THEREOF
US20250109138A1 (en) * 2020-12-09 2025-04-03 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
TW202241855A (zh) * 2021-01-27 2022-11-01 美商富曼西公司 用於防治無脊椎有害生物之唑類化合物
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
CA3217417A1 (en) 2021-05-05 2022-11-10 Kevin M. Guckian Compounds for targeting degradation of bruton's tyrosine kinase
MX2023013083A (es) * 2021-05-10 2024-01-08 Foghorn Therapeutics Inc Compuestos y usos de los mismos.
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
AU2022308734A1 (en) 2021-07-07 2024-02-22 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023287787A1 (en) 2021-07-13 2023-01-19 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
WO2023093728A1 (zh) * 2021-11-23 2023-06-01 江苏先声药业有限公司 Brm选择性降解剂化合物及其应用
US20250059198A1 (en) * 2021-11-24 2025-02-20 Arvinas Operations, Inc. Brm degrading compounds and associated methods of use
EP4436965A1 (en) * 2021-11-24 2024-10-02 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CA3239690A1 (en) * 2021-12-14 2023-06-22 Prazer Therapeutics Inc. Novel compound for degrading target protein or polypeptide by using polyubiquitination
JP2025502782A (ja) * 2021-12-28 2025-01-28 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム がん治療剤としての強力かつ選択的なｓｍａｒｃａ２分解キメラ分子
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
US20230416240A1 (en) 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
CN119384414A (zh) * 2022-06-30 2025-01-28 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用
CN115353468B (zh) * 2022-08-19 2023-06-30 安阳工学院 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法
KR20250107915A (ko) 2022-11-15 2025-07-14 프렐루드 테라퓨틱스 인코포레이티드 Brm 표적화 화합물 및 연관된 사용 방법
TW202444727A (zh) 2023-01-26 2024-11-16 美商艾維納斯手術有限公司 基於cereblon之kras降解protac及其相關用途
WO2024179529A1 (zh) * 2023-02-28 2024-09-06 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途
AR132905A1 (es) 2023-06-08 2025-08-06 Nurix Therapeutics Inc Degradadores selectivos bifuncionales de smarca2 y sus usos terapéuticos
WO2024256574A1 (en) * 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
UY40785A (es) 2023-06-14 2024-12-31 Astrazeneca Ab Degradadores de smarca2 y usos de los mismos antecedentes
WO2024256988A1 (en) 2023-06-14 2024-12-19 Astrazeneca Ab Smarca2 degraders and uses thereof
WO2024259341A2 (en) * 2023-06-16 2024-12-19 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2025094065A1 (en) * 2023-11-01 2025-05-08 Aurigene Oncology Limited Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
US20250161289A1 (en) 2023-11-10 2025-05-22 Prelude Therapeutics Incorporated KAT6 Targeting Compounds
WO2025106637A1 (en) * 2023-11-16 2025-05-22 Foghorn Therapeutics Inc. Cinnoline derivatives useful as baf modulators
WO2025131111A1 (zh) * 2023-12-22 2025-06-26 上海海雁医药科技有限公司 双环稠杂芳环衍生物及其药物组合物和用途
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP3139214B1 (en) 2003-12-03 2019-01-30 Nikon Corporation Exposure apparatus, exposure method, and device manufacturing method
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
HK1249058A1 (zh) 2015-03-18 2018-10-26 Arvinas, Inc. 用於增强靶向蛋白质降解的化合物和方法
CA2988430A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
RU2018105094A (ru) * 2015-07-13 2019-08-14 Арвинас, Инк. Модуляторы протеолиза на основе аланина и связанные с ними способы применения
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
CN107698657A (zh) 2017-09-26 2018-02-16 中国药科大学 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用
MX2020010368A (es) * 2018-04-01 2021-01-08 Arvinas Operations Inc Compuestos dirigidos a brm y métodos de uso asociados.

Also Published As

Publication number Publication date
CR20200527A (es) 2021-04-09
WO2019195201A1 (en) 2019-10-10
IL277677A (en) 2020-11-30
CN112166114B (zh) 2024-11-19
EP3774789A1 (en) 2021-02-17
SG11202008898UA (en) 2020-10-29
MY198308A (en) 2023-08-22
ES3027032T3 (en) 2025-06-12
CO2020013762A2 (es) 2021-01-18
PH12020500663A1 (en) 2021-06-07
KR20210005037A (ko) 2021-01-13
AU2019249849C1 (en) 2022-09-29
PL3774789T3 (pl) 2025-08-18
JP7721270B2 (ja) 2025-08-12
CA3094305A1 (en) 2019-10-10
HUE071391T2 (hu) 2025-08-28
LT3774789T (lt) 2025-06-25
US20240076295A1 (en) 2024-03-07
JP2023071767A (ja) 2023-05-23
JP2021520350A (ja) 2021-08-19
PE20212108A1 (es) 2021-11-04
US20190300521A1 (en) 2019-10-03
AU2024203058A1 (en) 2024-05-30
AU2019249849B2 (en) 2022-03-17
EP4537905A3 (en) 2025-06-25
FI3774789T3 (fi) 2025-06-17
KR20240130153A (ko) 2024-08-28
EP4537905A2 (en) 2025-04-16
HRP20250617T1 (hr) 2025-07-18
PT3774789T (pt) 2025-05-28
AU2019249849A1 (en) 2020-10-01
CL2020002546A1 (es) 2021-01-29
JP2025143253A (ja) 2025-10-01
BR112020020196A2 (pt) 2021-01-26
CN120504668A (zh) 2025-08-19
NZ767872A (en) 2024-04-26
RS66841B1 (sr) 2025-06-30
KR102697733B1 (ko) 2024-08-26
RU2020135754A3 (da) 2022-05-04
MX2020010368A (es) 2021-01-08
CN112166114A (zh) 2021-01-01
RU2020135754A (ru) 2022-05-04
AU2022204042A1 (en) 2022-06-30
MX2024000329A (es) 2024-01-25
SI3774789T1 (sl) 2025-07-31
EP3774789B1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3963021T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3870579T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3788045T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK4105223T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3852533T3 (da) Pyridazinoner og fremgangsmåder til anvendelse deraf
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
DK3828194T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf